CERE:NSD-Cerevel Therapeutics Holdings Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.38

Change

+0.02 (+0.05)%

Market Cap

USD 7.49B

Volume

0.77M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.48 (-0.84%)

USD 106.98B
MRNA Moderna Inc

+1.79 (+1.69%)

USD 38.83B
ARGX argenx NV ADR

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS

+0.69 (+2.51%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.40 (-0.28%)

USD 18.18B
RPRX Royalty Pharma Plc

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.26 (-1.53%)

USD 16.06B

ETFs Containing CERE

IBRN iShares Trust - iShares N.. 4.92 % 0.00 %

+0.38 (+1.67%)

USD 3.84M
MARB First Trust Vivaldi Merge.. 3.04 % 0.00 %

+0.06 (+1.67%)

USD 0.05B
EVNT AltShares Event-Driven ET.. 2.67 % 0.00 %

N/A

USD 4.44M
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+3.79 (+1.67%)

USD 1.24B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.63 (+1.67%)

USD 0.10B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+1.27 (+1.67%)

USD 7.05B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.05% 48% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.05% 48% F 46% F
Trailing 12 Months  
Capital Gain 70.41% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.41% 81% B- 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 18.76% 72% C 79% B-
Dividend Return 18.76% 72% C 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.01% 63% D 40% F
Risk Adjusted Return 43.63% 90% A- 77% C+
Market Capitalization 7.49B 97% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.